Replies to post #241857 on Biotech Values

[DewDiligence]

SBTX addendum—The company says it hopes to submit an IND (i.e. a request to start a phase-1 trial) for SBT8230 in 4Q22. As noted in the post I’m replying to, I think SBTX is flailing and there is little reason to think SBT8230 will be an effective agent in treating HBV.

[DewDiligence]

The SBT8230 HBV program is a very long longshot, IMHO.

Does anyone here disagree with the above? TIA